A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)
Clinical trial NCT06035497 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06035497
- Sponsor
- Bristol-Myers Squibb
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-11-20
- Primary completion
- 2027-01-30
- Enrollment
- 85
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.